Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Carney

Showing results (321-330 of 336) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Nature Genetics|September 21, 2010
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Ellen L Goode, Georgia Chenevix-Trench, Honglin Song, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Nature Genetics|September 21, 2010
Common variants at 19p13 are associated with susceptibility to ovarian cancerKelly L Bolton, Jonathan Tyrer, Honglin Song, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Human Genetics|November 6, 2013
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNAMadalene A Earp, Linda E Kelemen, Anthony M Magliocco, et al.
Cancer|December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyEun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Pageof 34

Showing results (321-330 of 336) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Nature Genetics|September 21, 2010
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Ellen L Goode, Georgia Chenevix-Trench, Honglin Song, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Nature Genetics|September 21, 2010
Common variants at 19p13 are associated with susceptibility to ovarian cancerKelly L Bolton, Jonathan Tyrer, Honglin Song, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Human Genetics|November 6, 2013
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNAMadalene A Earp, Linda E Kelemen, Anthony M Magliocco, et al.
Cancer|December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyEun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Pageof 34